<DOC>
	<DOC>NCT00080340</DOC>
	<brief_summary>The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.</brief_summary>
	<brief_title>Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Clinical diagnosis of nonsmall cell lung cancer Nonsmall cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation Failed two prior chemotherapy regimens which must have included platinum Measurable disease Treatment with more than two prior chemotherapy regimens History of bone marrow transplantation or stem cell support Pregnant or lactating women Known history of prior gefitinib therapy Known history of prior TLK286 therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
</DOC>